FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2526317542> ?p ?o ?g. }

• W2526317542 endingPage "1164e" @default.
• W2526317542 startingPage "1163" @default.
• W2526317542 abstract "Abstract Lessons Learned Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Despite lack of a reliable predictive biomarker in this disease, which may have partly contributed to the negative outcome reported here, linsitinib, although safe, showed no clinical activity in unselected, relapsed SCLC patients. Background. Treatment of relapsed small-cell lung cancer (SCLC) remains suboptimal. Insulin growth factor-1 receptor (IGF-1R) signaling plays a role in growth, survival, and chemoresistance in SCLC. Linsitinib is a potent IGF-1R tyrosine kinase inhibitor that potentially may be active against SCLC. Methods. In this phase II study, 8 eligible patients were randomly assigned in a 1:2 ratio to topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles) or linsitinib (150 mg orally twice daily until progression). The primary endpoint was progression-free survival. Patients with relapsed SCLC, platinum sensitive or resistant, performance status (PS) 0–2, and adequate hematologic, renal, and hepatic function were enrolled. Patients with diabetes, cirrhosis, and those taking insulinotropic agents were excluded. Crossover to linsitinib was allowed at progression. Results. Fifteen patients received topotecan (8 resistant, 3 with PS 2) and 29 received linsitinib (16 resistant, 5 with PS 2). Two partial responses were observed with topotecan. Only 4 of 15 patients with topotecan and 1 of 29 with linsitinib achieved stable disease. Median progression-free survival was 3.0 (95% confidence interval [CI], 1.5–3.6) and 1.2 (95% CI, 1.1–1.4) months for topotecan and linsitinib, respectively (p = .0001). Median survival was 5.3 (95% CI, 2.2–7.6) and 3.4 (95% CI, 1.8–5.6) months for topotecan and linsitinib, respectively (p = .71). Grade 3/4 adverse events (&gt;5% incidence) included anemia, thrombocytopenia, neutropenia/leukopenia, diarrhea, fatigue, dehydration, and hypokalemia for topotecan; and thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations for linsitinib. Conclusion. Linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients." @default.
• W2526317542 created "2016-10-07" @default.
• W2526317542 creator A5002341560 @default.
• W2526317542 creator A5002970130 @default.
• W2526317542 creator A5004712121 @default.
• W2526317542 creator A5015060656 @default.
• W2526317542 creator A5021617351 @default.
• W2526317542 creator A5027960464 @default.
• W2526317542 creator A5036587861 @default.
• W2526317542 creator A5055925608 @default.
• W2526317542 creator A5060537111 @default.
• W2526317542 creator A5062894702 @default.
• W2526317542 creator A5071469591 @default.
• W2526317542 creator A5076511437 @default.
• W2526317542 creator A5080538468 @default.
• W2526317542 date "2016-09-30" @default.
• W2526317542 modified "2023-09-26" @default.
• W2526317542 title "A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer" @default.
• W2526317542 cites W1999087873 @default.
• W2526317542 cites W2082185018 @default.
• W2526317542 cites W2097977881 @default.
• W2526317542 cites W2113146100 @default.
• W2526317542 cites W2141303400 @default.
• W2526317542 cites W2587797478 @default.
• W2526317542 cites W5234524 @default.
• W2526317542 doi "https://doi.org/10.1634/theoncologist.2016-0220" @default.
• W2526317542 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5061534" @default.
• W2526317542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27694157" @default.
• W2526317542 hasPublicationYear "2016" @default.
• W2526317542 type Work @default.
• W2526317542 sameAs 2526317542 @default.
• W2526317542 citedByCount "30" @default.
• W2526317542 countsByYear W25263175422017 @default.
• W2526317542 countsByYear W25263175422018 @default.
• W2526317542 countsByYear W25263175422019 @default.
• W2526317542 countsByYear W25263175422020 @default.
• W2526317542 countsByYear W25263175422021 @default.
• W2526317542 countsByYear W25263175422022 @default.
• W2526317542 countsByYear W25263175422023 @default.
• W2526317542 crossrefType "journal-article" @default.
• W2526317542 hasAuthorship W2526317542A5002341560 @default.
• W2526317542 hasAuthorship W2526317542A5002970130 @default.
• W2526317542 hasAuthorship W2526317542A5004712121 @default.
• W2526317542 hasAuthorship W2526317542A5015060656 @default.
• W2526317542 hasAuthorship W2526317542A5021617351 @default.
• W2526317542 hasAuthorship W2526317542A5027960464 @default.
• W2526317542 hasAuthorship W2526317542A5036587861 @default.
• W2526317542 hasAuthorship W2526317542A5055925608 @default.
• W2526317542 hasAuthorship W2526317542A5060537111 @default.
• W2526317542 hasAuthorship W2526317542A5062894702 @default.
• W2526317542 hasAuthorship W2526317542A5071469591 @default.
• W2526317542 hasAuthorship W2526317542A5076511437 @default.
• W2526317542 hasAuthorship W2526317542A5080538468 @default.
• W2526317542 hasBestOaLocation W25263175421 @default.
• W2526317542 hasConcept C121608353 @default.
• W2526317542 hasConcept C126322002 @default.
• W2526317542 hasConcept C143998085 @default.
• W2526317542 hasConcept C168563851 @default.
• W2526317542 hasConcept C203092338 @default.
• W2526317542 hasConcept C2776256026 @default.
• W2526317542 hasConcept C2776694085 @default.
• W2526317542 hasConcept C2779438470 @default.
• W2526317542 hasConcept C2780580887 @default.
• W2526317542 hasConcept C2781209748 @default.
• W2526317542 hasConcept C71924100 @default.
• W2526317542 hasConcept C90924648 @default.
• W2526317542 hasConceptScore W2526317542C121608353 @default.
• W2526317542 hasConceptScore W2526317542C126322002 @default.
• W2526317542 hasConceptScore W2526317542C143998085 @default.
• W2526317542 hasConceptScore W2526317542C168563851 @default.
• W2526317542 hasConceptScore W2526317542C203092338 @default.
• W2526317542 hasConceptScore W2526317542C2776256026 @default.
• W2526317542 hasConceptScore W2526317542C2776694085 @default.
• W2526317542 hasConceptScore W2526317542C2779438470 @default.
• W2526317542 hasConceptScore W2526317542C2780580887 @default.
• W2526317542 hasConceptScore W2526317542C2781209748 @default.
• W2526317542 hasConceptScore W2526317542C71924100 @default.
• W2526317542 hasConceptScore W2526317542C90924648 @default.
• W2526317542 hasIssue "10" @default.
• W2526317542 hasLocation W25263175421 @default.
• W2526317542 hasLocation W25263175422 @default.
• W2526317542 hasLocation W25263175423 @default.
• W2526317542 hasLocation W25263175424 @default.
• W2526317542 hasOpenAccess W2526317542 @default.
• W2526317542 hasPrimaryLocation W25263175421 @default.
• W2526317542 hasRelatedWork W2013085650 @default.
• W2526317542 hasRelatedWork W2037355330 @default.
• W2526317542 hasRelatedWork W2050376166 @default.
• W2526317542 hasRelatedWork W2053686268 @default.
• W2526317542 hasRelatedWork W2148484849 @default.
• W2526317542 hasRelatedWork W2186047679 @default.
• W2526317542 hasRelatedWork W2247399102 @default.
• W2526317542 hasRelatedWork W2387455091 @default.
• W2526317542 hasRelatedWork W2408182535 @default.
• W2526317542 hasRelatedWork W2978946191 @default.
• W2526317542 hasVolume "21" @default.
• W2526317542 isParatext "false" @default.
• W2526317542 isRetracted "false" @default.

• next